Loading...

NERV MINERVA NEUROSCIENCES INC US FDA Inspections 8-K Filing

MNRV

NRV

MINERVA NEUROSCIENCES INC

(NERV)

2024 8-K

Show Summary

Summary

Nasdaq Compliance

Nasdaq Compliance

Annual Meeting Results

Nasdaq Delisting Notice

Annual Meeting Notice

Resignation of Director

FDA Response Letter

Annual Meeting of Stockholders

Private Placement

Compliance Notice from Nasdaq

Resignation of Director

FDA Filing for New Drug App...

External Links:

Minerva Neurosciences, Inc. received a Complete Response Letter from the FDA regarding their New Drug Application for roluperidone for the treatment of negative symptoms in schizophrenia patients.

AI Assistant

MINERVA NEUROSCIENCES INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.